Marché de la découverte de médicaments à petites molécules – Analyse des tendances et de la croissance | Année de prévision 2031

  • Report Code : TIPRE00004774
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 173
Buy Now

Le marché de la découverte de médicaments à petites molécules était évalué à 24 976,14 millions de dollars américains en 2019 et devrait atteindre 50 823,06 millions de dollars américains d'ici 2027 ; il devrait croître à un TCAC de 9,5 % de 2020 à 2027.



Les médicaments à petites molécules sont utilisés dans l'administration ciblée de médicaments dans laquelle de petites molécules traversent la membrane cellulaire et agissent sur l'organite ou la protéine cellulaire spécifique . Les médicaments à petites molécules peuvent pénétrer facilement dans les cellules en raison de leur faible poids moléculaire. Ces molécules sont meilleures que les anticorps monoclonaux et autres médicaments à grandes molécules en raison de leur taille, de leur facilité de conversion en forme orale et de leur rapport coût-efficacité. Le marché de la découverte de médicaments à petites molécules devrait connaître une croissance énorme en raison de l'augmentation de l'approbation des médicaments à petites molécules, de la demande croissante de R&D de la part des organisations sous contrat et de l'adoption croissante des petites molécules dans les traitements des maladies chroniques. Cependant, le coût élevé de développement de médicaments devrait freiner la croissance du marché au cours de la période de prévision.





Régions lucratives pour le marché de la découverte de médicaments à petites molécules

Aperçu du marché



Adoption croissante des petites molécules dans le traitement des maladies chroniques



Selon les Centers for Disease Control (CDC), 6 adultes sur 10 souffrent d'une maladie chronique, telles que les maladies cardiaques, le diabète, le cancer, les maladies rénales, les maladies pulmonaires ou les accidents vasculaires cérébraux aux États-Unis, coûtant chaque année 3,5 billions de dollars américains à l'économie américaine pour le traitement de ces maladies chroniques. Les maladies chroniques sont la principale cause de décès dans le monde et leur nombre augmente chaque année. Par exemple, selon le CDC, plus de 1,6 million de personnes reçoivent un diagnostic de cancer chaque année aux États-Unis.



Les médicaments à petites molécules devraient fournir des options de traitement efficaces pour les maladies chroniques en raison de leur taille et de leur capacité. franchir les barrières cellulaires. Ils peuvent également être conçus pour traverser la barrière hémato-encéphalique afin de cibler les maladies neurologiques. Les petites molécules devraient jouer un rôle essentiel dans la réduction du fardeau des maladies chroniques. Dans les années à venir, les petites molécules devraient aider à la formulation de traitements plus efficients et efficaces pour les maladies chroniques.





Thérapeutique Area-Based Insights

Sur la base du domaine thérapeutique, le marché de la découverte de médicaments à petites molécules est segmenté en oncologie, système nerveux central, cardiovasculaire, respiratoire, orthopédie, immunologie, maladies rares et autres domaines thérapeutiques. Le segment de l'oncologie détenait la plus grande part du marché en 2019 en raison de l'augmentation des approbations de médicaments à petites molécules et de la croissance du portefeuille de traitements contre le cancer. De plus, l'augmentation des investissements en oncologie stimule davantage la croissance du segment. Par exemple, en décembre 2019, Zentalis Pharmaceuticals, une société biopharmaceutique au stade clinique axée sur le développement de nouvelles thérapies à petites molécules cliniquement différenciées ciblant les voies fondamentales du cancer, a réalisé un financement de série C de 85 millions de dollars américains. Cependant, le segment des maladies rares devrait enregistrer un TCAC plus élevé sur le marché au cours de la période de prévision.



Marché mondial de la découverte de médicaments à petites molécules, par domaine thérapeutique – 2019 & 2027



Insights basés sur le processus/la phase



Sur la base du processus/de la phase, le marché de la découverte de médicaments à petites molécules est segmenté en découverte de cible, validation de cible, génération et raffinement de prospects et développement préclinique . Le segment de la génération et du raffinement de leads détenait la plus grande part du marché mondial de la découverte de médicaments à petites molécules en 2019, en raison de l'augmentation des investissements dans la découverte de médicaments et de la demande croissante de thérapies rentables. De plus, la découverte de la cible implique l'identification de cibles modifiant la maladie, ce qui constitue l'une des étapes essentielles du pipeline de découverte de médicaments. Cependant, la découverte cible devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.



Perspectives stratégiques



Les collaborations et la stratégie d'expansion sont couramment adoptées par les entreprises pour étendre leur présence dans le monde et répondre aux demande croissante afin d'élargir son portefeuille de produits.



Les acteurs du marché opérant sur le marché de la découverte de médicaments à petites molécules ont adopté la stratégie d'innovation de produits pour répondre à l'évolution de la demande des clients à travers le monde, ce qui permet également aux acteurs de maintenir leur nom de marque à l'échelle mondiale.



Marché de la découverte de médicaments à petites molécules – Par domaine thérapeutique




  • Oncologie

  • Système nerveux central

  • Cardiovasculaire

  • Respiratoire

  • Orthopédie

  • Immunologie

  • Maladies Rares

  • Autres Domaines Thérapeutiques

  • Marché de la découverte de médicaments à petites molécules – Par processus/phase




    • Découverte de cibles

    • Validation de cibles

    • Génération et raffinement de prospects
    • Développement préclinique


    Marché de la découverte de médicaments à petites molécules – Par zone géographique




    • Amérique du Nord

      • États-Unis

      • Canada

      • Mexique



    • Europe

      • France

      • Allemagne

      • Italie< /li>
      • Royaume-Uni

      • Espagne

      • Reste de l'Europe



    • Asie-Pacifique (APAC)

      • Chine

      • Inde

      • Corée du Sud

      • Japon

      • Australie

      • Reste de l'APAC

      • < /ul>
      • Moyen-Orient et Afrique (MEA)

        • Afrique du Sud

        • Arabie saoudite

        • EAU

        • Reste de MEA



      • Amérique du Sud (SAM)

        • Brésil

        • Argentine

        • Reste de SAM



      Profils des entreprises




      • Johnson and Johnson Services, Inc.

      • Teva Pharmaceutical Industries Ltd

      • Boehringer Ingelheim International GmbH

      • Allergan Plc.

      • Pfizer Inc.

      • Bristol-Myers Squibb Company

      • MERCK KGaA
      • GlaxoSmithKline plc.

      • AstraZeneca

      • Gilead Sciences, Inc.


Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is small molecule drug discovery market?

Small molecules drugs are used in targeted drug delivery in which small molecules pass through the cell membrane and acts on the specific cellular organelle or protein. The small molecules drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their size, easy convertibility to oral form and cost affectivity. The discovery of novel small molecule entities that are capable of specific interactions represents a significant challenge in the early stages of drug discovery. When the biological target is well defined and understood, the rational design of small molecule ligands is possible. In the recent years, the small molecules have witnessed significant attention over biologics, as there is an increasing demand for these drugs.

What are the driving factors for the small molecule drug discovery market across the globe?

The factors that are driving growth of the market are increasing approval of small molecule drugs, growing demand for R&D from contract organizations, and rising adoption of small molecules in chronic disease treatments propel the growth of the market.

Who are the major players in the small molecule drug discovery market?

The small molecule drug discovery market majorly consists of the players such as Pfizer Inc., Bristol-Myers Squibb Company, Merck KGaA, GlaxoSmithKline Plc, AstraZeneca, Johnson & Johnson Services, Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Boehringer Ingelheim International GmbH, and Allergan Plc.

The List of Companies - Small Molecule Drug Discovery Market

  1. Johnson and Johnson Services, Inc.
  2. Teva Pharmaceutical Industries Ltd
  3. Boehringer Ingelheim International GmbH
  4. Allergan Plc.
  5. Pfizer Inc.
  6. Bristol-Myers Squibb Company
  7. MERCK KGaA
  8. GlaxoSmithKline plc.
  9. AstraZeneca
  10. Gilead Sciences, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports